Vitamin D Status in Children With Sickle Cell Disease Living in Lyon, France

Overview

Vitamin D deficiency may be under-diagnosed in sickle cell disease French children. Therefore, the investigator need an epidemiologic study about the prevalence of vitamin D deficiency in this specific population. There are not specific guidelines neither testing nor treatment. The investigator propose to test vitamin D status in all children with sickle cell disease who are consulting their referring haematologist doctor or in the emergency ward.

Full Title of Study: “Evaluation of Vitamin D Deficiency Distribution in Children With Sickle Cell Disease Followed in Lyon, France”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: February 1, 2023

Interventions

  • Biological: 25-OH Vitamin D measure
    • As a complement to the off-study prescription, the investigator are taking two 1 mL tubes of extra blood to measure vitamin D, calcium, phosphorus, parathyroid hormone (PTH) and creatinine.

Arms, Groups and Cohorts

  • Sickle cell disease children from Lyon, France
    • Sickle cell disease children, followed in IHOPe (Institut d’Hématologie et d’Oncologie Pédiatrique) center, consulting their referring haematologist doctor or in emergency ward, with prescribed blood sample.

Clinical Trial Outcome Measures

Primary Measures

  • Determination of 25-OH Vitamin D level
    • Time Frame: Day 1
    • We classify vitamin D status as follows : Sufficiency > >75nmol/L (>30 ng/mL) Insufficiency 50-75 nmol/L (20-30 ng/mL) Deficiency 12-50nmol/L (5-20 ng/mL) Severe deficiency <12 nmol/L (<5 ng/mL)

Participating in This Clinical Trial

Inclusion Criteria

  • Children: under 18 years old – Sickle cell any genetic type homozygous or composite heterozygous – To receive an assessment independently of the study, during a presentation to the emergency ward and/or a follow-up consultation by the hematologist – no parental opposition signed by at least one parent/legal representative and no child opposition – social security beneficiary Exclusion Criteria:

  • History of hematologic grafting

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 17 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hospices Civils de Lyon
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Valérie LAUNAY, MD, Principal Investigator, Urgences pédiatriques de l’Hôpital Femme Mère Enfant – Hospices Civils de Lyon
  • Overall Contact(s)
    • Valérie LAUNAY, MD, 04 27 85 62 13, valerie.launay@chu-lyon.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.